Valeritas Hosts Educational Symposium and Participates in the Metabolic & Endocrine Disease Summit (MEDS) East
October 03, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock
October 02, 2019 07:00 ET
|
Valeritas, Inc.
- Debt Exchange Expected to Save Approximately $8 Million in Cash Interest Expense - - Provides Corporate Updates Including Expectation That Third Quarter U.S. Revenue Will Grow 30% Over Prior Year -...
Valeritas Announces Participation on “The Cutting Edge of Cannabinoid Science” Panel at the CBD Expo EAST Conference
September 26, 2019 09:31 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Presents Positive h-Patch™ CBD Study Data at CannMed Conference
September 24, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Announces Presentation of Preclinical h-Patch™ CBD Study at CannMed Conference
September 19, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia
September 17, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
September 12, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Announces Oral Presentation of Preclinical h-Patch™ CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
September 03, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its...
Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 29, 2019 16:05 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,...
Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint
August 15, 2019 07:00 ET
|
Valeritas, Inc.
BRIDGEWATER, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one,...